UK-based Orchard Therapeutics Plc has enlisted Brad Mathis to lead its US commercial operations ahead of the expected approval and launch of up to three ex vivo gene therapies for rare diseases. Mr Mathis was recently head of US commercial operations at Sucampo Pharmaceuticals Inc where he helped prepare for the launch of a product for Niemann-Pick Type C disease. Prior to this, he was an executive at Alexion Pharmaceuticals Inc.
Orchard also appointed Robin Kenselaar as general manager for commercial operations in Europe, the Middle East and Africa.
Orchard announced the appointment on 8 November 2018.
Copyright 2018 Evernow Publishing Ltd